Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20816018 | 1.00 | KMT2A (0.57) | KMT2ASMN1; SMN2MAOBMEN1LMNA | |
| SCHEMBL20816012 | 0.89 | LMNA (0.47) | KMT2ASMN1; SMN2MAOBMEN1LMNA | |
| SCHEMBL20816014 | 0.89 | LMNA (0.47) | KMT2ASMN1; SMN2MAOBMEN1LMNA | |
| SCHEMBL4568931 | 0.88 | KMT2A (0.54) | KMT2ASMN1; SMN2MAOBMEN1LMNA | |
| SCHEMBL29818935 | 0.88 | LMNA (0.46) | KMT2ASMN1; SMN2MAOBMEN1LMNA | |
| SCHEMBL29818894 | 0.86 | LMNA (0.45) | KMT2ASMN1; SMN2MEN1LMNAHPGD | |
| SCHEMBL8181061 | 0.86 | KMT2A (0.58) | KMT2ASMN1; SMN2MAOBMEN1LMNA | |
| SCHEMBL3443080 | 0.86 | KMT2A (0.58) | KMT2ASMN1; SMN2MAOBMEN1LMNA | |
| SCHEMBL9188249 | 0.86 | KMT2A (0.58) | KMT2ASMN1; SMN2MAOBMEN1LMNA | |
| SCHEMBL10632490 | 0.86 | MAPK1 (0.64) | KMT2ASMN1; SMN2MAOBMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10565015-B2 | Spiroketal-based C2-symmetric scaffold for asymmetric catalysis | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190084995-A1 | Spiroketal-Based C2-Symmetric Scaffold For Asymmetric Catalysis | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-03-21 | — | — | US | disclosed |
| EP-1874768-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113837-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10565015-B2 | Spiroketal-based C2-symmetric scaffold for asymmetric catalysis | PKD2, OPA1, PKD1 | KMT2A 3015/4885SMN1; SMN2 2336/4885MAOB 969/4885 |
| US-20190084995-A1 | Spiroketal-Based C2-Symmetric Scaffold For Asymmetric Catalysis | PKD2, OPA1, PKD1 | KMT2A 3015/4885SMN1; SMN2 2336/4885MAOB 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.